retatrutide phase 2 trial results weight loss just delivered the first top-line 3 for a triple agonist in obesity — and the findings from TRIUMPH-4 are striking👇 28.7% Weight Loss in New

Targeting metabolism, insulin resistance, and diabetes to treat nonalcoholic steatohepatitis

PMID 12451146

Amycretin oral formulations helped patients lose up to 13.1% of their weight within 12 weeks

Hypotension consider reducing antihypertensive medicines before initiating treatment or before a dose increase Diabetic ketoacidosis (DKA) increased risk (see below) SGLT-2 inhibitor use is associated with an increased risk of severe DKA People taking SGLT-2 inhibitors are at increased risk of DKA, particularly in the first few months of treatment or peri-operatively

one common approach began at 0.5 mg once weekly , with incremental increases at approximately four-weekly intervals up to target maintenance doses of 4 mg, 8 mg, or 12 mg once weekly

It may be tempting to reuse needles, but doing so can lead to skin infections and bruising